Excerpts

While the lack of QoL data in a negative clinical trial can be considered almost insignificant, a positive trial represents the first step for a drug to obtain regulatory approval and be included in clinical guidelines and routine clinical practice.

When we evaluated the efficacy of CEA levels as a prognostic tool, we observed an elevated trend of serum CEA levels within the first 3 months after diagnosis, which may indicate a high risk of progression.

Compared to baseline, TRFT resulted in highly significant improvements in both ADAS cog 13 and Rey AVLT recall ( Figure 3 A,B)—a stunning reversal of AD cognitive impairment.

Although the incidence of non-cardia GC has declined in many regions—attributed to reduced Helicobacter pylori prevalence, improved food preservation, and dietary changes—an increasing trend in adenocarcinomas of the gastric cardia and esophagogastric junction has been observed, particularly in high-income countries [ 4 ].

The mortality rates for TCC at all four tract sites, however, have shown an increasing trend over the same time period.

[ 46 ] noted that higher BMI, particularly in obese patients (BMI ≥ 25 kg/m 2 ), was associated with a 25% lower risk of disease progression (HR = 0.75; 95% CI: 0.62–0.92), with a significant trend of decreasing progression risk with increasing BMI.

We found that mFOLFIRINOX was associated with significantly improved disease-free survival and a favorable trend toward better overall survival, independent of histological subtype.

Similarly, patients with low hemoglobin levels, below 12 g/dL, indicating anemia, also showed a trend toward earlier disease progression.

Following initiation of therapy, both patient-reported and parent-reported outcomes showed a trend towards improvement and subsequently remained stable throughout the duration of treatment. 4.

In one study, a DNA microanalysis of samples from adult AML patients showed a trend for high levels of PRAME mRNA to correlate with improved overall survival (OS) [ 8 ].

As a result, only genes with highly significant and large differential changes in expression among all datasets were retained in the analysis.

Primary Endpoint: Total Radiation Dose The primary analysis revealed highly significant differences in total radiation exposure among techniques ( Figure 4 ).

The volcano plot summarizes effect sizes and statistical confidence, highlighting the dense cluster of highly significant, tumor-elevated genes ( Figure 1 ). 3.2.

Other comorbid conditions such as peripheral artery disease, high New York Heart Association (NYHA) functional class, and chronic renal and pulmonary disease are also highly significant, albeit with a lower odds ratio.

60.7%, p = 0.049), while BRCA mutations showed a favorable trend.

These findings suggest that supportive care needs are similar across dosing strategies, with a possible trend toward more treatment interruptions in the fixed-dose group.

Patients who received immunotherapy and had an ECOG-PS of 0 ( n = 73) showed a trend towards a worse mOS in the early TG (15 m; 95% CI = 4.32–25.68 vs. 20 m; 95% CI = 9.05–31.00).

Unsupervised hierarchical clustering based on these epifactor expressions also showed a trend toward the reclassification of molecular subtypes in the Williamson dataset ( Figure 4 H).

However, in the recently reported TRUST trial [ 29 ], upfront surgery showed significantly improved median PFS (22.2 months) and showed a trend toward longer overall survival (OS) (54 months), compared to neoadjuvant chemotherapy, followed by interval cytoreductive surgery (19.7 months and 48.3 months, respectively.

Similarly, analysis of clinical data from The Cancer Genome Atlas-Breast Invasive Carcinoma (TCGA-BRCA) cohort reveals a positive correlation between WWOX expression and E-cadherin levels, alongside a negative trend with fibronectin levels in TNBC samples.

For the five top selected radiomic features, we observed that they had a clear trend of either increase or decrease based on the risk of lung cancer development ( Figure 2 b), as stratified in 4 groups including the “<1-year” group for those diagnosed within a year, the “1–3 year” group for patients diagnosed between one and three years, and for “>3-year” and “>7-year” groups for individuals diagnosed after more than three and seven years, respectively.

Regarding prognostic impact, our data show a favorable trend in overall survival for patients who received targeted therapies guided by ctDNA results.

Third, although patients under 60 years of age showed a trend toward higher rates of stage IV disease and distant metastasis at diagnosis, these differences did not reach statistical significance.

showed a trend towards hypermethylation in normal tissue, although not statistically significant.

In patients with viral HCC (HBV or HCV), the subgroup analysis showed a trend toward a better outcome, suggesting that nonviral HCC may benefit less from immunotherapy.